Intel's shares dropped 22% in after-hours trading following its fourth-quarter revenue forecast of $15 billion to $16 billion, which fell short of the $17.1 billion market expectation by $1.1 billion to $2.1 billion. A large long position on Intel stock held by a Hyperliquid wallet, valued around $7.57 million, faced an unrealized loss amid the sell-off. The position's liquidation price was significantly below its entry price, highlighting the risk faced by investors betting on a price rise. This revenue outlook shortfall signals challenges ahead for Intel and may impact investor confidence going forward.
Intel's shares fell sharply after hours, providing context for readers. For those tracking the broader market, as of Oct 30, 2026 09:01 WIB, only 4 of 50 major cryptocurrencies on Pluang rose while 45 fell. Among these, SNX dropped 10.39% with 100% sell order activity, contrasting with ENJ which fell 9.95% but saw 94% buy orders, and FIL down 9.86% with a more balanced 44% sell / 56% buy split.
As 2027 nears, cancer research is making strides worldwide with AI aiding treatment development, precision medicine tailoring therapies to tumor biology, and new clinical trials showing improved survival. Initiatives like Anthropic's support for chil...
FirstCash Holdings, Inc. shares fell 14.75% on October 22, 2026, after the company reported a 28% year-over-year decline in operating income for its American First Finance segment and a 15% drop in lease and loan originations for Q3. The decline was ...
First Hawaiian, Inc. and TriCo Bancshares have received shareholder approval for First Hawaiian's acquisition of TriCo, pending customary closing conditions. This merger aims to combine their banking services and expand their capacity to serve custom...
Venture capitalist Tim Draper warned that businesses could eventually reject dollars in favor of bitcoin, leading to bank runs as demand for fiat currencies declines. He reiterated his $250,000 bitcoin price forecast, now expected by October 2027, an...
Aspen Neuroscience, a biotech company focused on regenerative medicine for Parkinson's disease, priced its initial public offering at $15 per share, offering 9.375 million shares to raise approximately $140.6 million. The company plans to use the pro...
